Exelixis, Inc. (EXEL) vs Incyte Corporation (INCY)
- Exelixis, Inc. EXEL 62.11 −1.15%
- Incyte Corporation INCY 112.95 −0.28%
Exelixis, Inc. and Incyte Corporation are both Biotechnology companies. Incyte Corporation is the larger, with a market value of $23.0B against $15.6B — 1.5× the size. Incyte Corporation trades at the lower P/E: 13.9× against 18.8×. Incyte Corporation grew revenue faster over the last twelve months: 26.9% against 9.23%. Exelixis, Inc. has the higher net margin (35.3% vs 27.7%) and the lower return on invested capital (60.5% vs 60.5%). Across the 22 metrics below, Incyte Corporation leads on 13 and Exelixis, Inc. on 9.
Valuation
Profitability
| Metric | EXEL | INCY | Biotechnology median |
|---|---|---|---|
| Gross margin | 96.48% | 92.62% | 65.16% |
| Operating margin | 39.88% | 30.56% | 0.00% |
| Net margin | 35.33% | 27.71% | 0.00% |
| Free cash flow margin | 47.55% | 32.48% | 0.00% |
| Return on equity | 44.39% | 30.67% | (56.36%) |
| Return on assets | 33.28% | 23.55% | (48.04%) |
| Return on invested capital | 60.45% | 60.50% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack